DAY ONE26 November, 2020

DAY ONE NOVAMBER 26

13:00 - 14:00

Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study

Mohamed Rahal

Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).

Shawqi Bazarbashi

A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.

Ashwaq Alolayan

Ashwaq Alolayan Abdullah alsharmAhmed Alshehri

14:00 - 14:30

Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.

Abdullah Alshorm

SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA).

Jamal Zikri

Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): Results of the phase II-portion—A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.

Abdulraheem Shanqiti

14:30 - 15:30

15:30 - 16:30

16:30 - 17:30

A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapyalone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).

Meteb Alfuhaidi

Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).

Essam Murshid

ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.

Ahmed Alwabari

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

Ibrahim Madkhali

TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).

Ahmed Al-Shehri

PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer.

Shady Khayat

18:15 - 19:15

19:15 - 20:15

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.

Abdullah Al Tuwairqi

Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated Results from the phase III CASPIAN study. Turki Alfaye

KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).

Ahmed Alfaraj

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.

Khalid Alsaleh

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs chemo (4 cycles) as first-line (1L) treatment for stage IV or recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.

Hamed Alhussaini

Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival Samer Abushelah

20:15 - 21:15

DAY ONE NOVAMBER 26

13:00 - 13:15 Dr. Lulu AbduljabarFirst 2-Year Results of the Multicenter, Randomized IMRT-MC2 Trial (MINT): Intensity-ModulatedRadiotherapy with Simultaneous Integrated Boost Versus 3-D-Conformal Radiotherapywith Consecutive Boost for Breast Cancer Patients.

13:15 – 13:30 Dr. Hussain Al-Amoudi Reconstruction Outcomes in a Multi-Institution Prospective Phase II Hypofractionated Post-Mastectomy Radiation Therapy trial.

13:30 – 13:45 Dr. Chaker zaidiHeterogeneity in Outcomes Among Women with Clinically Node-Positive Breast Cancer and Axillary Pathologic Complete Response: An Analysis of NSABP B18, B27, B40, and B41.

13:45 – 14:00 Dr. Ahmed HussainClinical Evaluation of a Deep Learning Model for Segmentation of Nodal Clinical Target Volumes in Breast Cancer Radiotherapy

14:00 – 14:15 Discussion for 1st Session

14:25 – 14:40 Dr. Ameen Al- OmairStereotactic Ablative Fractionated Radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A Randomized Phase II Trial.

14:40 – 14:55 Dr. Omar Iskanderani Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with COVID-19-Related Pneumonia.

14:55 – 15:10 Dr. Mohammed AttarIndividualized Adaptive Radiotherapy versus Standard Radiotherapy with Chemotherapy for Patients with Locally Advanced Non- Small Cell Lung Cancer: A Multicenter Randomized Phase III Clinical Trial CRTOG1601.

15:10 – 15:25 Dr. Mohammad Al-MaghrabiMolecular Biomarkers for Chemo-radiotherapy Response in Unresectable Limited Stage Small Cell Lung Cancer.

15:25 – 15:40 Discussion for 2nd Session

15:55 – 16:10 Dr. Zaid JastaniahComplete clinical response after short course radiation and sequential multi-agent chemotherapy for non-operative treatment of rectal adenocarcinoma

16:10 – 16:25 Dr. Yasser SorourNon-operative management versus surgery in patients with complete endoscopic response to neoadjuvant therapy for rectal cancer.

16:25 – 16:40 Dr. Saif Al-ThagafiStereotactic Body Radiotherapy vs Trans-arterial Chemo-embolization in locally advanced hepatocellular carcinoma (HERACLES: HEpatocellular carcinoma stereotactic RAdiotherapy CLinical Efficacy Study).

16:40 – 16:55 Dr. Bilal JalalSynthetic CT-aided Online CBCT Multi-Organ Segmentation for CBCT-guided Adaptive Radiotherapy of Pancreatic Cancer.

16:55 – 17:10 Discussion for 3rd Session

17:20 – 17:35 Dr. Mohammad Al-DohaimDevelopment of Advanced Preselection Tools to Reduce Unnecessary Plan Comparisonsin Model-Based Selection of Head and Neck Cancer Patients for Proton Therapy.

17:35 – 17:50 Dr. Hussain Al-Hussain Defining Radiotherapy (RT) Coverage for Non-Melanoma Skin Cancer (NMSC) Using Mohs Micrographic Surgery (MMS) Margins.

17:50 – 18:05 Dr. Hatim MarzogiRisk and Predictors of Late Lower Cranial Neuropathy in Long-term Oropharyngeal Cancer Survivors treated with definitive radiotherapy: A Retrospective Cohort Study among 1,988 Survivors.

18:05 – 18:20 Dr. Naser Al-DhaibaniCardiovascular Event Reporting in Clinical Trials Involving Chest Radiation Therapy.

18:20 – 18:35 Discussion for 4th Session

DAY TWO27 November, 2020

DAY TWO NOVAMBER 27

10:00 - 11:30

Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall responseversus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acutemyeloid leukemia (ND-AML).

Solaf Khanfar

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versusbrentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL) Ayman Hejazi

Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).

Musa Alzhrani

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

Majed Alahmadi

Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.

Enas Mutaher

ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM).

Mohamed Bakkar

11:30 - 13:30

13:30 - 14:30

14:30 - 15:30

15:30 - 16:30

Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20.

Abdul Aziz Babaeer

Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

Fisal Azam

A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. Waleed Alselwi

16:30 - 17:30

17:30 - 18:30

Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008).

Reyad Dada

Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).

Rola Mufti

Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo(PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). Hulayel Alharbi

18:30 - 19:30

Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastaticmelanoma (MM) resistant to PD1 monotherapy.

Ahmed Badheeb

Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012). Waleed Alselwi

Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19). Majed Algahel

19:30 - 20:30

Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.

Ndal Bukhari

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. faisal Albadinah

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260). Mubarak Almansour

DAY TWO NOVAMBER 27

10:00 - 10:15 Dr. Ibrahim Al-OtainStereotactic radiosurgery versus whole-brain radiation therapy for patients with 4-15 brain metastases: A phase III randomized controlled trial.

10:15 – 10:30 Dr. Maged Al-GhamdiCCTG SC.24/TROG 17.06: A Randomized Phase II/III Study Comparing 24Gy in 2 Stereotactic Body Radiotherapy (SBRT) Fractions Versus 20Gy in 5 Conventional Palliative Radiotherapy (CRT) Fractions for Patients with Painful Spinal Metastases.

10:30 – 10:45 Dr. Ali BalbaidRadiotherapy (RT) dose-intensification (DI) using intensity-modulated RT (IMRT) versus standard-dose (SD) RT with Temozolomide (TMZ) in newly diagnosed glioblastoma (GBM): Preliminary results of NRG Oncology BN001.

10:45 – 11:00 Dr. Hossam Al-AssafClassification of patients at imminent risk of death at the time of palliative radiotherapy consultation.

11:00 – 11:15 Discussion 5th Session

13:00 - 13:15 D. Huda Al-TukhiEffective Pain Control with Very Low Dose Palliative Radiotherapy for Multiple Myeloma Patients with Painful Osseous Lesions.

13:15 – 13:30 Dr. Taghreed Al HindiAssessing the Role of Radiation Therapy for Primary Mediastinal Large B-Cell Lymphoma in the Setting of PET Avid Disease after Chemotherapy

13:30 – 13:45 Dr. Ibrahim Al-OmariA Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma.

13:45 – 14:00 Dr. Shakir Al-ShakirA Pilot Trial Using Telehealth in Radiation Oncology: The Future of Healthcare is Virtual.

14:00 – 14:15 Discussion 6th Session

14:25 – 14:40 Dr. Yasir Al-AyedUltra-Hypofractionated versus Conventionally Fractionated Radiation Therapy Boost for Patients with High-Risk, Localized Prostate Cancer: A 5-Year Results from Randomized HYPO-PROST Trial.

14:40 – 14:55 Dr. Saad Al-RasheediStereotactic radiotherapy for oligoprogression in metastatic kidney cancer patient receiving tyrosine kinase inhibitors therapy: a prospective phase II multi-center study.

14:55 – 15:10 Dr. Hussam HejaziBladder Preservation with Twice-Daily Radiation plus 5-Flourouracil/Cisplatin or Daily Radiation plus Gemcitabine for MIBC – Updated Results of NRG/RTOG 0712: A Randomized Phase 2 Trial

15:10 – 15:25 Dr. Rania HashemStereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Randomized Trial

15:25 – 15:40 Discussion (15 minutes)

15:55 – 16:10 Dr. Hala AL-LaithyPhase III randomized trial of postoperative adjuvant conventional radiation (3DCRT) versus image guided intensity modulated radiotherapy (IG-IMRT) in cervical cancer (PARCER): Final Analysis.

16:10 – 16:25 Dr. Nesreen AwadAssessment of Impact of Bone Marrow Sparing for Hematological and Gastrointestinal Toxicities in Cervical Cancer with External Beam Radiation Therapy

16:25 – 16:40 Dr. Hanadi HabibullahElective inguinal node irradiation is not necessary in cervical cancer invading lower third of vagina.

16:40 – 16:55 Dr. Wamied AbdulrahmanFLASH Dose Rate Effect on Circulating Immune Cells: A Potential Mechanism for FLASH-RT?

16:55 – 17:10 Discussion ( 15 minutes )

Main Page copyPage 1 copyNew Agenda copyNew Agenda 2 copylilly 1lilly 2New Agen∂a ∂åy 1 copyNew Agen∂a ∂åy 11 copyphizer 1phizer 2phizer 3Page 2 copyNew Agenda day 2 copyNew Agenda day 22 copyrocheNew Agen∂a ∂åy 2 copyNew Agen∂a ∂åy 22 copyAstratake∂aTake∂a 2